We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
TABRECTA Novartis Pharmaceuticals Australia Pty Ltd
Product name
TABRECTA
Accepted date
Jun-2025
Active ingredients
capmatinib hydrochloride
Proposed indication
TABRECTA is for the treatment in adult patients with non-small cell lung cancer (NSCLC) that has spread throughout the body. It is for NSCLC with a particular genetic change (a MET exon 14 skipping mutation).
Application type
A (new medicine)
Publication date
Jun-2025